Molecular imaging societies have numerous recommendations for patients with diabetes who undergo fluoride-18 fluorodeoxyglucose (FDG) PET/CT tumor imaging. According to new research published in the Journal of the American College of Radiology, however, many providers are not explaining these things to patients when appointments are scheduled. {read more here}